Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | NMRA |
---|---|---|
09:32 ET | 15323 | 13.03 |
09:34 ET | 3175 | 13.075 |
09:36 ET | 2000 | 13.17 |
09:38 ET | 1850 | 13.13 |
09:39 ET | 2640 | 13.34 |
09:41 ET | 3511 | 13.34 |
09:43 ET | 500 | 13.29 |
09:45 ET | 550 | 13.269 |
09:48 ET | 996 | 13.3 |
09:50 ET | 2259 | 13.41 |
09:54 ET | 300 | 13.375 |
09:57 ET | 1050 | 13.35 |
09:59 ET | 1894 | 13.2175 |
10:03 ET | 1934 | 13.28 |
10:06 ET | 200 | 13.3 |
10:08 ET | 100 | 13.295 |
10:10 ET | 500 | 13.24 |
10:12 ET | 709 | 13.27 |
10:14 ET | 1750 | 13.41 |
10:15 ET | 450 | 13.41 |
10:21 ET | 409 | 13.41 |
10:28 ET | 900 | 13.365 |
10:30 ET | 100 | 13.405 |
10:32 ET | 786 | 13.43 |
10:33 ET | 7331 | 13.65 |
10:35 ET | 2027 | 13.51 |
10:44 ET | 1300 | 13.48 |
10:46 ET | 25300 | 13.51 |
10:48 ET | 1500 | 13.461 |
10:50 ET | 1700 | 13.485 |
10:53 ET | 3895 | 13.46 |
10:55 ET | 100 | 13.48 |
10:57 ET | 100 | 13.47 |
11:00 ET | 100 | 13.45 |
11:02 ET | 400 | 13.46 |
11:04 ET | 401 | 13.43 |
11:08 ET | 500 | 13.435 |
11:09 ET | 100 | 13.43 |
11:11 ET | 1400 | 13.39 |
11:18 ET | 200 | 13.385 |
11:22 ET | 900 | 13.46 |
11:24 ET | 300 | 13.42 |
11:26 ET | 700 | 13.35 |
11:27 ET | 1100 | 13.385 |
11:29 ET | 200 | 13.385 |
11:31 ET | 200 | 13.4 |
11:33 ET | 1850 | 13.43 |
11:36 ET | 1060 | 13.485 |
11:38 ET | 3600 | 13.5 |
11:40 ET | 200 | 13.495 |
11:42 ET | 4022 | 13.5756 |
11:44 ET | 300 | 13.58 |
11:45 ET | 4626 | 13.62 |
11:47 ET | 300 | 13.61 |
11:49 ET | 936 | 13.61 |
11:51 ET | 1242 | 13.63 |
11:54 ET | 200 | 13.64 |
11:56 ET | 300 | 13.63 |
11:58 ET | 200 | 13.62 |
12:00 ET | 644 | 13.62 |
12:02 ET | 4774 | 13.63 |
12:03 ET | 100 | 13.605 |
12:07 ET | 100 | 13.62 |
12:09 ET | 2641 | 13.62 |
12:12 ET | 650 | 13.625 |
12:14 ET | 100 | 13.6341 |
12:16 ET | 2707 | 13.61 |
12:18 ET | 5110 | 13.6 |
12:20 ET | 1375 | 13.6 |
12:21 ET | 2716 | 13.62 |
12:23 ET | 1800 | 13.6 |
12:25 ET | 700 | 13.615 |
12:27 ET | 2400 | 13.61 |
12:32 ET | 7832 | 13.61 |
12:34 ET | 1400 | 13.635 |
12:36 ET | 100 | 13.635 |
12:38 ET | 200 | 13.635 |
12:39 ET | 1660 | 13.65 |
12:41 ET | 300 | 13.655 |
12:43 ET | 200 | 13.66 |
12:48 ET | 300 | 13.65 |
12:50 ET | 1516 | 13.68 |
12:52 ET | 608 | 13.68 |
12:54 ET | 100 | 13.67 |
12:56 ET | 2461 | 13.68 |
12:57 ET | 1398 | 13.66 |
12:59 ET | 100 | 13.64 |
01:01 ET | 125 | 13.65 |
01:03 ET | 100 | 13.65 |
01:08 ET | 200 | 13.655 |
01:10 ET | 26500 | 13.67 |
01:12 ET | 9205 | 13.625 |
01:14 ET | 250 | 13.63 |
01:15 ET | 200 | 13.64 |
01:17 ET | 300 | 13.635 |
01:19 ET | 1828 | 13.65 |
01:21 ET | 550 | 13.66 |
01:28 ET | 200 | 13.65 |
01:30 ET | 1525 | 13.655 |
01:32 ET | 1200 | 13.64 |
01:35 ET | 100 | 13.65 |
01:37 ET | 200 | 13.64 |
01:39 ET | 2201 | 13.665 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Neumora Therapeutics Inc | 2.2B | -8.2x | --- |
Celldex Therapeutics Inc | 2.1B | -11.1x | --- |
Keros Therapeutics Inc | 2.2B | -11.7x | --- |
Centessa Pharmaceuticals PLC | 2.2B | -10.5x | --- |
Akero Therapeutics Inc | 2.0B | -8.4x | --- |
Vera Therapeutics Inc | 2.3B | -18.6x | --- |
Neumora Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company’s therapeutic pipeline consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Its advanced product candidate, navacaprant (NMRA-140), is a novel once-daily oral kappa opioid receptor (KOR) antagonist that is being developed for the treatment of depressive disorder (MDD). Its other candidates include NMRA-266, NMRA-511, and NMRA-NMDA. NMRA-266 is a positive allosteric modulator program of the M4 muscarinic receptor (M4R) for the treatment of schizophrenia. NMRA-266 is designed to be selective for the M4 receptor subtype of the muscarinic receptor family. NMRA-511 is an investigational antagonist of the vasopressin 1a receptor (V1aR). NMRA-NMDA is an NMDA positive allosteric modulator program that the Company is developing for the treatment of schizophrenia.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $2.2B |
---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 160.0M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $-1.66 |
Book Value | $2.95 |
P/E Ratio | -8.2x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.